Disclaimer:

Medidex is not a provider of medical services and all information is provided for the convenience of the user. No medical decisions should be made based on the information provided on this website without first consulting a licensed healthcare provider.This website is intended for persons 18 years or older. No person under 18 should consult this website without the permission of a parent or guardian.

Nexesta Fe

×

Overview

What is Nexesta Fe?

Nexesta Fe is a combinational contraceptive containing the progestational compound norethindrone and the estrogenic compound ethinyl estradiol. The packaging includes 21 white to off-white tablets composed of norethindrone and ethinyl estradiol followed by 7 brown ferrous fumarate (placebo) tablets. The chemical name for norethindrone is 17-hydroxy-19-nor-17α-pregn-4-en-20-yn-3-one and for ethinyl estradiol the chemical name is 19-nor-17α-pregna-1,3,5 (10)-trien-20-yne-3, 17-diol. The structural formulas are:

The active white to off-white Nexesta Fe (norethindrone and ethinyl estradiol tablets USP (chewable) 0.4 mg/0.035 mg and ferrous fumarate tablets (chewable)) tablets contain 0.4 mg norethindrone USP and 0.035 mg ethinyl estradiol USP and the following inactive ingredients: anhydrous lactose, colloidal silicon dioxide, dibasic calcium phosphate, dihydrate, lactose monohydrate, magnesium stearate, nat spearmint, povidone, sodium starch glycolate, and sucralose. The brown tablets contain croscarmellose sodium, ferrous fumarate, lactose monohydrate, magnesium stearate, microcrystalline cellulose, nat spearmint, povidone, and sucralose. The ferrous fumarate tablets do not serve any therapeutic purpose.

USP dissolution test is pending.



What does Nexesta Fe look like?



What are the available doses of Nexesta Fe?

Nexesta Fe consists of 28 tablets in the following order ():

What should I talk to my health care provider before I take Nexesta Fe?

How should I use Nexesta Fe?

Nexesta Fe is indicated for use by females of reproductive potential to prevent pregnancy.

Nexesta Fe is dispensed in a blister pack . Nexesta Fe may be started using either a Day 1 start or a Sunday start (see Table 1). For the first cycle of a Sunday Start regimen, an additional method of contraception should be used until after the first 7 consecutive days of administration.


What interacts with Nexesta Fe?

Sorry No Records found


What are the warnings of Nexesta Fe?

Sorry No Records found


What are the precautions of Nexesta Fe?

Sorry No Records found


What are the side effects of Nexesta Fe?

Sorry No records found


What should I look out for while using Nexesta Fe?

Do not prescribe Nexesta Fe to women who are known to have the following conditions:

 • A high risk of arterial or venous thrombotic diseases. Examples include women who are known to:

      o Smoke, if over age 35       o Have deep vein thrombosis or pulmonary embolism, now or in the past       o Have inherited or acquired hypercoagulopathies       o Have cerebrovascular disease       o Have coronary artery disease       o Have thrombogenic valvular or thrombogenic rhythm diseases of the heart (for example, subacute bacterial endocarditis with valvular disease, or atrial fibrillation)       o Have uncontrolled hypertension       o Have diabetes mellitus with vascular disease       o Have headaches with focal neurological symptoms or have migraine headaches with aura           o Women over age 35 with any migraine headaches  • Liver tumors, benign or malignant, or liver disease  • Undiagnosed abnormal uterine bleeding  • Pregnancy, because there is no reason to use COCs during pregnancy  • Breast cancer or other estrogen- or progestin-sensitive cancer, now or in the past  • Hypersensitivity to any of the components.  • Use of Hepatitis C drug combinations containing ombitasvir/paritaprevir/ritonavir, with or without dasabuvir, due to the potential for ALT elevations

C

igarette smoking increases the risk of serious cardiovascular events from combination oral contraceptive (COC) use. This risk increases with age, particularly in women over 35 years of age, and with the number of cigarettes smoked. For this reason, COCs are contraindicated in women who are over 35 years of age and smoke


What might happen if I take too much Nexesta Fe?

There have been no reports of serious ill effects from overdosage of oral contraceptives, including ingestion by children. Overdosage may cause withdrawal bleeding in females and nausea.


How should I store and handle Nexesta Fe?

Store at 20º-25º C (68º-77º F); excursions permitted to 15 to 30º C (59 to 86º F) [see USP Controlled Room Temperature].WELLBUTRIN XL Extended-Release Tablets, 150 mg of bupropion hydrochloride, are creamy-white to pale yellow, round tablets printed with "WELLBUTRIN XL 150" in bottles of 30 tablets (NDC 0187-0730-30) and 90 tablets (NDC 0187-0730-90). WELLBUTRIN XL Extended-Release Tablets, 300 mg of bupropion hydrochloride, are creamy-white to pale yellow, round tablets printed with "WELLBUTRIN XL 300" in bottles of 30 (NDC 0187-0731-30). Store at 25°C (77°F); excursions permitted to 15° to 30°C (59° to 86°F) [see USP Controlled Room Temperature].WELLBUTRIN XL tablets may have an odor.WELLBUTRIN XL Extended-Release Tablets, 150 mg of bupropion hydrochloride, are creamy-white to pale yellow, round tablets printed with "WELLBUTRIN XL 150" in bottles of 30 tablets (NDC 0187-0730-30) and 90 tablets (NDC 0187-0730-90). WELLBUTRIN XL Extended-Release Tablets, 300 mg of bupropion hydrochloride, are creamy-white to pale yellow, round tablets printed with "WELLBUTRIN XL 300" in bottles of 30 (NDC 0187-0731-30). Store at 25°C (77°F); excursions permitted to 15° to 30°C (59° to 86°F) [see USP Controlled Room Temperature].WELLBUTRIN XL tablets may have an odor.WELLBUTRIN XL Extended-Release Tablets, 150 mg of bupropion hydrochloride, are creamy-white to pale yellow, round tablets printed with "WELLBUTRIN XL 150" in bottles of 30 tablets (NDC 0187-0730-30) and 90 tablets (NDC 0187-0730-90). WELLBUTRIN XL Extended-Release Tablets, 300 mg of bupropion hydrochloride, are creamy-white to pale yellow, round tablets printed with "WELLBUTRIN XL 300" in bottles of 30 (NDC 0187-0731-30). Store at 25°C (77°F); excursions permitted to 15° to 30°C (59° to 86°F) [see USP Controlled Room Temperature].WELLBUTRIN XL tablets may have an odor.WELLBUTRIN XL Extended-Release Tablets, 150 mg of bupropion hydrochloride, are creamy-white to pale yellow, round tablets printed with "WELLBUTRIN XL 150" in bottles of 30 tablets (NDC 0187-0730-30) and 90 tablets (NDC 0187-0730-90). WELLBUTRIN XL Extended-Release Tablets, 300 mg of bupropion hydrochloride, are creamy-white to pale yellow, round tablets printed with "WELLBUTRIN XL 300" in bottles of 30 (NDC 0187-0731-30). Store at 25°C (77°F); excursions permitted to 15° to 30°C (59° to 86°F) [see USP Controlled Room Temperature].WELLBUTRIN XL tablets may have an odor.


×

Clinical Information

Chemical Structure

No Image found
Clinical Pharmacology

COCs lower the risk of becoming pregnant primarily by suppressing ovulation. Other possible mechanisms may include cervical mucus changes that inhibit sperm penetration and endometrial changes that reduce the likelihood of implantation.

Non-Clinical Toxicology
Do not prescribe Nexesta Fe to women who are known to have the following conditions:

 • A high risk of arterial or venous thrombotic diseases. Examples include women who are known to:

      o Smoke, if over age 35       o Have deep vein thrombosis or pulmonary embolism, now or in the past       o Have inherited or acquired hypercoagulopathies       o Have cerebrovascular disease       o Have coronary artery disease       o Have thrombogenic valvular or thrombogenic rhythm diseases of the heart (for example, subacute bacterial endocarditis with valvular disease, or atrial fibrillation)       o Have uncontrolled hypertension       o Have diabetes mellitus with vascular disease       o Have headaches with focal neurological symptoms or have migraine headaches with aura           o Women over age 35 with any migraine headaches  • Liver tumors, benign or malignant, or liver disease  • Undiagnosed abnormal uterine bleeding  • Pregnancy, because there is no reason to use COCs during pregnancy  • Breast cancer or other estrogen- or progestin-sensitive cancer, now or in the past  • Hypersensitivity to any of the components.  • Use of Hepatitis C drug combinations containing ombitasvir/paritaprevir/ritonavir, with or without dasabuvir, due to the potential for ALT elevations

C

igarette smoking increases the risk of serious cardiovascular events from combination oral contraceptive (COC) use. This risk increases with age, particularly in women over 35 years of age, and with the number of cigarettes smoked. For this reason, COCs are contraindicated in women who are over 35 years of age and smoke

Sulfacetamide preparations are incompatible with silver preparations.

• Stop Nexesta Fe if an arterial thrombotic event or venous thromboembolic (VTE) event occurs.

• Stop Nexesta Fe if there is unexplained loss of vision, proptosis, diplopia, papilledema, or retinal vascular lesions. Evaluate for retinal vein thrombosis immediately

• If feasible, stop Nexesta Fe at least 4 weeks before and through 2 weeks after major surgery or other surgeries known to have an elevated risk of VTE as well as during the following prolonged immobilization.

• Start Nexesta Fe no earlier than 4 weeks after delivery, in women who are not breastfeeding. The risk of postpartum VTE decreases after the third postpartum week, whereas the risk of ovulation increases after the third postpartum week.

• The use of COCs increases the risk of  VTE. However, pregnancy increases the risk of VTE as much or more than the use of COCs. The risk of VTE in women using COCs is 3 to 9 per 10,000 woman-years. The risk of VTE is highest during the first year of use of COCs and when restarting hormonal contraception after a break of 4 weeks or longer. The risk of thromboembolic disease due to COCs gradually disappears after use is discontinued.

 Use of COCs also increases the risk of arterial thromboses such as strokes and myocardial infarctions, especially in women with other risk factors for these events. COCs have been shown to increase both the relative and attributable risks of cerebrovascular events (thrombotic and hemorrhagic strokes).  The risk increases with age, particularly in women over 35 years of age who smoke.

• Use COCs with caution in women with cardiovascular disease risk factors.

The following serious adverse reactions with the use of COCs are discussed elsewhere in the labeling:

The following adverse reactions are commonly reported by COC users. Because these reactions are voluntarily reported by from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure:

×

Reference

This information is obtained from the National Institute of Health's Standard Packaging Label drug database.
"https://dailymed.nlm.nih.gov/dailymed/"

While we update our database periodically, we cannot guarantee it is always updated to the latest version.

×

Review

Rate this treatment and share your opinion


Learn about User Reviews

Helpful tips to write a good review:

  1. Only share your first hand experience as a consumer or a care giver.
  2. Describe your experience in the Comments area including the benefits, side effects and how it has worked for you. Do not provide personal information like email addresses or telephone numbers.
  3. Fill in the optional information to help other users benefit from your review.

Reason for Taking This Treatment

(required)

Click the stars to rate this treatment

Effectiveness (required)

This medication has worked for me.




Ease of Use (required)

This medication has been easy for me to use.




Satisfaction (required)

Overall, I have been satisfied with my experience.




Write a brief description of your experience with this treatment:

2000 characters remaining

Optional Information

Help others benefit from your review by filling in the information below.
I am a:
Gender:
×

Professional

Clonazepam Description Each single-scored tablet, for oral administration, contains 0.5 mg, 1 mg, or 2 mg Clonazepam, USP, a benzodiazepine. Each tablet also contains corn starch, lactose monohydrate, magnesium stearate, microcrystalline cellulose, and povidone. Clonazepam tablets USP 0.5 mg contain Yellow D&C No. 10 Aluminum Lake. Clonazepam tablets USP 1 mg contain Yellow D&C No. 10 Aluminum Lake, as well as FD&C Blue No. 1 Aluminum Lake. Chemically, Clonazepam, USP is 5-(o-chlorophenyl)-1,3-dihydro-7-nitro-2H-1,4-benzodiazepin-2-one. It is a light yellow crystalline powder. It has the following structural formula: C15H10ClN3O3 M.W. 315.72
×

Tips

Tips

×

Interactions

Interactions

A total of 440 drugs (1549 brand and generic names) are known to interact with Imbruvica (ibrutinib). 228 major drug interactions (854 brand and generic names) 210 moderate drug interactions (691 brand and generic names) 2 minor drug interactions (4 brand and generic names) Show all medications in the database that may interact with Imbruvica (ibrutinib).